The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
英國藥品和醫療保健產品監管局（MHRA）向cel-sci授予了多基因治療藥物multikine在18歲以下兒童人群中用於頭頸部腫瘤治療的產品特定豁免
CEL-SCI Corporation (NYSE:CVM) today reported it has received a decision letter from the United Kingdom's Healthcare Products Regulatory Agency (MHRA) granting Multikine (Leukocyte Interleukin, Injection)* a product specific waiver for the treatment of head and neck cancer in a pediatric population of people up to 18 years of age. As a result, CEL-SCI will not be required to evaluate Multikine in a pediatric population as part of license and marketing clearance review in the UK.
cel-sci 公司（紐交所:CVM）今天報告稱，已收到英國醫療產品管制局（MHRA）的決定函，授予Multikine（白細胞白細胞介素，注射）*在18歲以下兒童人群中治療頭頸癌的產品特定豁免。因此，CEL-SCI將無需在英國對Multikine進行18歲以下兒童人群的評估，作爲許可和營銷許可審查的一部分。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。